Michelle Zhang

Michelle Zhang has nearly 20 years of oncology drug discovery and development experience in both biotech (Curis and Biomed Valley Discoveries) and big pharma (Novartis Institutes for Biomedical Research). Her R&D expertise spans across small molecule, antibody, antibody-drug-conjugate, protein and radiopharmaceutical therapeutic and diagnostic modalities. She has led numerous programs from early discovery, translational research, non-clinical evaluations into clinical development, including a number of clinical candidate selections, IND submissions and Phase 1/2 clinical studies. Michelle received her Ph.D. in Biochemistry from Harvard University.